BF 1
Alternative Names: BF-1Latest Information Update: 08 Sep 2021
At a glance
- Originator Biofrontera AG
- Class Antimigraines
- Mechanism of Action Serotonin 2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Migraine
Most Recent Events
- 08 Sep 2021 Phase-I clinical trials ongoing in Migraine (Prevention) in Netherlands (PO) (Biofrontera AG company pipeline, September 2021)
- 28 May 2018 No recent reports of development identified for phase-I development in Migraine(Prevention) in Netherlands (PO, Tablet)
- 10 May 2016 Phase I development is ongoing in the Netherlands